PA
ZVRA icon

Profund Advisors’s Zevra Therapeutics ZVRA Stock Holding History

Profund Advisors’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$223K Buy
15,526
+1,780
+13% +$19.8K 0.01% 1016
2026
Q1 		$128K Sell
13,746
-4,332
-24% -$39K ﹤0.01% 1061
2025
Q4 		$162K Buy
18,078
+888
+5% +$8.4K ﹤0.01% 1200
2025
Q3 		$163K Buy
+17,190
New +$172K 0.01% 1009
2025
Q1 		– Sell
-12,055
Closed -$101K – 1119
2024
Q4 		$101K Buy
+12,055
New +$103K ﹤0.01% 1068

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Profund Advisors's ZVRA Position: Q2 2026 in Review

Profund Advisors increased its Zevra Therapeutics (ZVRA) stake by 13% in Q2 2026, buying an estimated $19.8K and bringing the position to 15,526 shares worth $223K. The position accounts for 0.01% of the portfolio, ranked #1016.

Profund Advisors first reported a position in ZVRA in Q4 2024 and has held it in 5 quarters since. 158 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Profund Advisors held 15,526 shares of Zevra Therapeutics worth $223K as of Q2 2026.
  • Profund Advisors bought 1,780 Zevra Therapeutics shares in Q2 2026, an estimated $19.8K.
  • Zevra Therapeutics made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #1016 holding.
  • Profund Advisors first reported a position in Zevra Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • 158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.